エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF

Size: px
Start display at page:

Download "エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF"

Transcription

1 IF g 3mg(0.3%) Deprodone Propionate ( ) ( ) F A X IF

2 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF A4 9 IF IF IF 11 1 IF IF 4. IF IF MR IF IF MR Drug Safety Update IF

3

4

5 (1) (2) (3) 84.3%(721 /855 ) 96.3%(823 /855 ) 81.4%(664 / %(765 /816 ) 78.5%(520 / %(613 /662 ) (4) 1.0%(9 /859 ) 2.1%(17 /824 ) 1.6%(12 /728 ) - 1 -

6 0.3% 0.3% 0.3% ECLAR OINTMENT 0.3%, ECLAR CREAM 0.3%, ECLAR LOTION 0.3% JAN Deprodone Propionate INN C24H32O (+)-11,17-dihydroxy-1,4-pregnadiene-3,20-dione 17-propionate - 2 -

7 CAS

8 Britton-Robinson (ph210) ( / ) D α g 20mL100mm - 4 -

9 (1) 2mg 2mL 365nm 10mL (2) (1100)1mL 1mL 2 (3) 0.05g 2mL 5 272mL 1 (4) ( ) - 5 -

10 - 6 -

11 1g 3mg0.3 ph (200 ) 3 50m 0.5% ph HP2100-O( ) HP2101C( ) HP2102L( ) 1g 3mg

12 1) - 8 -

13 1) 2) - 9 -

14 1) 0.7g( 2mg ) 10mL 10 30mL 10 1mL 1mL 2 2) 0.7g 10mL 10 30mL 10 1mL 0.02g 10mL 5L (60:15:10:3) 12cm ( 365nm) Rf (0.3) 1) 0.7g( 2mg ) 30mL 30mL 2 1mL 1mL 2 2) 0.7g 30mL 30mL 2 1mL 0.02g 10mL 5L (60:15:10:3) 12cm ( 365nm) Rf (0.3) 1) 0.7g( 2mg ) 20mL 2g 30mL 2 1mL 1mL

15 2) 0.7g 20mL 2g 30mL 2 1mL 0.02g 10mL 5L (60:15:10:3) 12cm ( 365nm) Rf (0.3) 1)3) 0.7g( 2mg ) 20mL 2g 30mL 3 100mL 10mL 10mL g 100mL 2mL 50mL 10mL 10mL 20L QT QS (mg) (mg)qt/qs1/25 n- (120000)

16 ( ) ( ) ( )

17 - 13 -

18 DNA RNA DNA mrna mrna mrna 7)8) 30mg (p<0.01) (p<0.01)

19

20 DP-O Control DP-O 34 5 BV-O DP-O DP-C Control DP-C 34 5 BV-C DP-C ( ) 2 50mg 11) (mg) (%) (mg/100gb.w.) Control DP-O DP-O **,## 31.9 (34.2 a ) **,# BV-O ** **,$$ ( S.E.) DP-O 7 Control DP-O BV-O DP-O BV-O DP-O

21 (mg) (%) (mg/100gb.w.) Control DP-C * DP-C **,## 40.9 (41.7 a ) ** BV-C ** **,$$ ( S.E.) DP-C 7 Control DP-C BV-C DP-C BV-C DP-C BV-O Control 3 (17 )7 (21 ) DP-O BV-O 3 (17 ) 7 (21 ) DP-O BV-O

22 ( ) mg

23 1) 14) 5 2g( 6mg)12 EIA (DP) 12 6,11,17- -1,4- -3, (M2) (4pg/mL)

24 - 20 -

25 20 2g( 6mg) (4pg/mL) 0.06%

26 AUC (pghr/mL) AUC (pghr/mL) AUC (pghr/mL) Kel (hr -1 ) Kel (hr -1 ) Kel (hr -1 ) 7880(%)

27 CYP %

28 2-24 -

29 ODT 3, (0.43%) 4 (0.11%) 4 (0.11%) 4 (0.11%) 4 (0.11%) 2, (1.60%) 13 (0.61%) 7 (0.54%) 6 (0.28%) 5 (0.24%) 5 (0.24%) (1.65) 6 (0.82%) 5 (0.69%) 4 (0.55%) ( ) ODT

30 - 26 -

31 ODT (ODT)

32 - 28 -

33 17) 2) ( ) 80mg/kg 18)19) 1) (SD 5 n=20 20) 0.04mg/kg/day15 2) ( n=3 3) 0.2mg/kg/day13 2mg/kg/day 3) ( n=2 2) 0.1mg/kg/day 1 5mg/kg/day 50mg/kg/day 2 18) 1) (SD 5 n=30 30) mg/kg/day 52 (4 ) 0.04mg/kg/day 0.01mg/kg/day 2) ( n=6 6) mg/kg/day 0.01mg/kg/day 0.01mg/kg/day

34 SD 6 (n=20) 60 (n=20) mg/kg/day 0.08mg/kg/day 0.6mg/kg/day 0.6mg/kg/day 0.08mg/kg/day 0.08mg/kg/day 0.01mg/kg/day (SD 10 n=30) mg/kg/day 0.08mg/kg/day 10mg/kg/day 0.08mg/kg/day ( n=12) mg/kg/day 2mg/kg/day 0.4mg/kg/day 0.08mg/kg/day (SD 10 n=25) mg/kg/day 0.01mg/kg/day 0.08mg/kg/day 0.08mg/kg/day 0.6mg/kg/day 24) (Hartley n=5) ASA PCA 24) (Hartley ) 24) (Hartley ) Maximization

35 25) 3H AUC H AUC H- (0.1mg/kg) H- (0.4mg/kg)

36 (SD ) 3H- (0.6mg/kg) % 8.6% 11.2% 12% (SD ) 3H- (0.6mg/kg) % 10.5% 13.3% 14% 18 3H- 24 ( 0.4mg/kg)

37 g105g5010g10 500g 5g105g5010g10 10g1010g

38 AM 760 4AM AMZ M N Q

39 1) ( ) 2) ( ) 3) ( ) 4) ( ) 5) 0.3%Deprodone Propionate (DP ) 5(9)159,1989 6) DP ( ) 7) 67(10)1935,1985 8) Therapeutic Research5(6)955,1986 9) ( ) 10) DP DP ( ) 11) Deprodone Propionate(DP) ( ) 23(15)93, ) DP-L( ) ( ) 13) Deprodone propionate ( ) 14) ( ) 15) Deprodone propionate(dp) ( ) 16) ( ) 17) DP ( ) 18) ( ) 19) Deprodone Propionate(DP) (6)7, ) Deprodone Propionate(DP) 24(6)25, ) Deprodone Propionate(DP) 24(6)37, ) Deprodone Propionate(DP) 24(6)59, ) ( ) 24) Deprodone Propionate(DP) ( ) 23(15)7,

40 25) ( ) 26) ( ) 27) Deprodone Propionate ( ) 23(15)103, ) ( ) 29) ( ) 30) ( )

41 - 37 -

42 - 38 -

43 MKI10506G ECL DB003A

1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF

1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF 2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR

More information

IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF

IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF 2008 2 3 87269 IF19989 100g 700g 30g SucrosePovidoneIodine 1999 3 15 1999 7 9 2000 5 IF 2008 2 IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF 1981

More information

IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF

IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF 200823 877122 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment 200821 19518 19977 IF20082 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug

More information

グリセオール注インタビューフォーム

グリセオール注インタビューフォーム 2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10

More information

untitled

untitled ~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/

More information

エコリシン点眼液/眼軟膏インタビューフォーム

エコリシン点眼液/眼軟膏インタビューフォーム 2011 11 4 871319 1mL 5mg 5mg15 1g 5mg 5mg15 JAN JAN Erythromycin LactobionateJAN Colistin Sodium MethanesulfonateJAN 1970 3 31 1970 8 1 1970 7 20 TEL0120-921-839 06-6321-7056 9 17 https://www.santen.co.jp/medical/admin/a300.jsp

More information

:,, : - 7 -

:,, : - 7 - 31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6

More information

エディロールカプセルインタビューフォーム

エディロールカプセルインタビューフォーム 2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/

More information

RF_1

RF_1 RF_1 10/04/16 10:32 http://rftechno.web.infoseek.co.jp/rf_1.html 1/12 RF_1 10/04/16 10:32 http://rftechno.web.infoseek.co.jp/rf_1.html 2/12 RF_1 10/04/16 10:32 http://rftechno.web.infoseek.co.jp/rf_1.html

More information

1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR

More information

199004_渓仁会_年次報告書

199004_渓仁会_年次報告書 () () () () () () () () () () () () () () () (4) (5) (6) 4 (7) 5 (8) 6 (9) 7 () 8 () 7 4 5 () 6 () 6 7 9 () 4 () 4 () 4 () 4 () 4 () 4 () 4 () 4 () 44 45 () 4 46 () 48 () 48 () 49 () 49 5 () 5 () 5 ()

More information

, 360ml P , 360ml P , 360ml P , 40, 720ml P , 14, 2

, 360ml P , 360ml P , 360ml P , 40, 720ml P , 14, 2 3-1 3-1 20 2600, 20, 360ml P.35 3-2 3-2 16 2700, 16, 280ml P.35 3-3 3-3 20 2600, 20, 360ml P.35 3-4 3-4 19 2600, 19, 340ml P.35 3-5 3-5 20 2900, 20, 360ml P.35 3-6 3-6 18 3000, 18, 320ml P.35 3-7 3-7 18

More information

% %

% % 4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5

More information

DPCはやわかり表紙_2014_H1-H4.indd

DPCはやわかり表紙_2014_H1-H4.indd C O N T E N T S 1 2 3 4 5 6 7 A B AB 15 15 25 2SD 1 1 A B 15 AB 25 2SD 1 1 1 A B 25 2SD 10 10 10 AB 1 1 1 1 A 1 A 1 B1 15 B 2SD 8 9 10 11 12 13 14 15 16 17 18 DPCA DPCA 7 DPCA DPCA 7 DPCA DPCA 7 DPCA DPCA

More information

20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine

More information

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12 (1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132

More information

裁定審議会における裁定の概要 (平成23年度)

裁定審議会における裁定の概要 (平成23年度) 23 23 23 4 24 3 10 11 12 13 14 () 1 23 7 21 23 12 14 (19 ) 30 1.876% 60 8 24 19 78 27 1 (10) 37 (3) 2 22 9 21 23 5 9 21 12 1 22 2 27 89 10 11 6 A B 3 21 12 1 12 10 10 12 5 1 9 1 2 61 ( 21 10 1 11 30 )

More information

和県監査H15港湾.PDF

和県監査H15港湾.PDF ...1...1...1...1...1...1...1...1...2...2...2...3...3...3...5...5...10...11...12...13...13...13...14...14...14...14...14...14...15...15...15...15...15 ...16...17 14...17...18...18...19...21...23 2...25...27...27...28...28...28

More information

untitled

untitled () () () () () ( ) () ( ) () ( ) () 2 () () 2 () () ( ) () () () 2 () () 2 3 ( ) () ( ) 2 3 4 () () 2 3 4 () () ( )( ) ( ) 2 ( ) 3 () () 2 3 () () 2 3 () () () () () () () () (( ) ( ) (( ))( )( ) ) 2 3

More information

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30

More information

... 6

... 6 ... 6 1) 2) No. 01 02 03 04 05 06 07 08 09 10 11 12 No. 1 2 2 3 3cm 4

More information

untitled

untitled 1....1 2....2 2.1...2 2.2...2 3....14 3.1...14 3.2...14 4....15 4.1...15 4.2...18 4.3...21 4.4...23 4.5...26 5....27 5.1...27 5.2...35 5.3...54 5.4...64 5.5...75 6....79 6.1...79 6.2...85 6.3...94 6.4...

More information

113 120cm 1120cm 3 10cm 900 500+240 10 1 2 3 5 4 5 3 8 6 3 8 6 7 6 8 4 4 4 4 23 23 5 5 7

More information

untitled

untitled 21 14 487 2,322 2 7 48 4 15 ( 27) 14 3(1867) 3 () 1 2 3 ( 901923 ) 5 (1536) 3 4 5 6 7 8 ( ) () () 9 10 21 11 12 13 14 16 17 18 20 1 19 20 21 22 23 21 22 24 25 26 27 28 22 5 29 30cm 7.5m 1865 3 1820 5

More information

1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24

1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24 15 4 16 1988 63 28 19314 29 3 15 4 16 19283 15294 16 1930 113132 3 15 4 16 33 13 35 12 3 15 4 16 1945 10 10 10 10 40 1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11

More information

Microsoft Word - 入居のしおり.doc

Microsoft Word - 入居のしおり.doc 1 1 2 2 2 3 2 4 3 5 3 6 3 7 3 8 4 1 7 2 7 3 7 4 8 5 9 6 9 7 10 8 10 9 11 10 11 11 11 12 12 13 13 1 14 2 17 3 18 4 19 5 20 6 22 (1) 24 (2) 24 (3) 24 (4) 24 (5) 24 (6) 25 (7) 25 (8) 25 (9) 25 1 29 (1) 29

More information

( )

( ) ( ) () () 3 cm cm cm cm cm cm 1000 1500 50 500 1000 1000 1500 1000 10 50 300 1000 2000 1000 1500 50 10 1000 2000 300 50 1000 2000 1000 1500 50 10 1000 2000 300 30 10 300 1000 2000 1000 1500 1000

More information

2002 (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (8) No 2,500 3 200 200 200 200 200 50 200 No, 3 1 2 00 No 2,500 200 7 2,000 7

More information

-26-

-26- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- cm -39- -40- 1 2 3 4 4 3 2 1 5 5-41- -42- -43- -44- -45- -46- -47- -48- -49- -50- cm -51- -52- -53- -54- -55- -56- -57- -58- -59- -60-

More information

-1- 4 1 2 4-2- -- 2 2 cm 0 80cm 2 80cm 80cm 80cm 50cm 80cm 50cm 6 80cm 100 50 50 cm 10 6 4 50cm 4 4 50cm -4- -5- cm 50cm 4 4 4 50cm 50cm 4 80cm 50cm 80cm 50cm 6 cm -6- 20 250cm 1 2 1 4 0cm 60cm cm cm 1

More information

河川砂防技術基準・基本計画編.PDF

河川砂防技術基準・基本計画編.PDF 4 1 1 1 1 1 2 1 2.1 1 2.2 2 2.3 2 2.4 2 3 2 4 3 2 4 1 4 1.1 4 1.2 4 2 4 2.1 4 2.2 4 2.3 5 2.4 5 2.5 5 2.5.1 5 2.5.2 5 2.6 5 2.6.1 5 2.6.2 5 2.6.3 5 2.6.4 5 2.6.5 6 2.7 6 2.7.1 6 2.7.2 6 2.7.3 6 2.7.4

More information

4 100g

4 100g 100g 10 20 30 40 50 60 70 80 4 5 7 9 12 15 19 24 60 100 10 80 100 20 10 5 20 195 20-1- 60 60 15 100 60 100 15 15 15 100 15 15 60 100 10 60 100 100 15 10 10 60 100 15 10 15 10 5-2- 80 80 24 100 80 100 24

More information

年次報告書-2003年(平成15年)度版-

年次報告書-2003年(平成15年)度版- 9876 ,g,g,g,9g 8 6 6 6 6 8 7 8 6 7 8 7 9 7 6 6 6 7 7 8 6 8 7 6 6 8 7 8 7 7 9 7 6 98 76,8 () ( ) 8,68.7 7,76, 9,87.9 8,67, () g g g g g g g g g g g g g g g g g g g g g g g g g g g g () () 9 8 88 6 8 88

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

55 a h dd s q q w w w d d d d d d d d d

55 a h dd s q q w w w d d d d d d d d d 54 q w e r q w e 55 a h dd s q q w w w d d d d d d d d d w e r d q 56 57 ggg gg w e g g g g g g g g g g g g g g g g 58 r o o 59 o o o o o o o o 60 o o o o o o o 61 t f q w e o 62 g q 63 w e 64 r 65 t qw

More information

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF 2009 2 1 872612 IF 1998 9 IODINE M DISINFECTANT SOLUTION 10 10w/v 100mL 10g( 1g) PovidoneIodine 2008 10 15 2008 12 19 2009 1 6 IF 2008 12 IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF

More information

untitled

untitled - 1 - - 2 - OFF - 3 - 18-4 - - 5 - - 6 - (1) (2) No 1 0099240130 CL-10 2 0099240040 CL-3-7 - - 8 - 50Hz 250 / - 9 - 6. 1 6. 2 R 6. 3 V 6. 4 R - 10 - 6. 5 6. 6 6. 7-11 - 6. 8 500mm 6. 9 4. 6. 10-12 - 6.

More information